CAMP4 Therapeutics (NASDAQ:CAMP) Coverage Initiated by Analysts at Oppenheimer

Key Points

• Oppenheimer initiated coverage of CAMP4 Therapeutics with an “outperform” rating and a $15 price target, implying approximately 275% upside from the reported $4 share price.
• Analyst sentiment is generally positive: seven analysts rate the stock a Buy, one a Hold and one a Sell, producing a “Moderate Buy” consensus rating and an average price target of $10.86.
• CAMP4 reported a quarterly loss of $0.58 per share, substantially wider than the $0.24 consensus estimate, while insiders sold far more shares than they purchased over the past 90 days.

Analysts at Oppenheimer started coverage on shares of CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) in a research report issued to clients and investors on Monday, Briefing.com reports. The brokerage set an "outperform" rating and a $15.00 price target on the Wireless communications provider's stock. Oppenheimer's price objective would suggest a potential upside of 275.00% from the company's current price.

Several other brokerages also recently commented on CAMP. UBS Group set a $15.00 target price on CAMP4 Therapeutics in a research note on Friday, August 14th. Zacks Research raised CAMP4 Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Monday, August 17th. JPMorgan Chase & Co. raised CAMP4 Therapeutics from a "neutral" rating to an "overweight" rating and upped their target price for the stock from $5.00 to $9.00 in a research report on Tuesday, June 16th. Chardan Capital cut their target price on CAMP4 Therapeutics from $6.50 to $6.00 and set a "buy" rating on the stock in a report on Tuesday, September 29th. Finally, Piper Sandler reissued an "overweight" rating and issued a $15.00 price target (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $10.86.

CAMP4 Therapeutics Price Performance

Shares of CAMP stock opened at $4.00 on Monday. The firm has a 50 day moving average of $4.16 and a 200-day moving average of $4.26. The company has a market cap of $251 million, a price-to-earnings ratio of -1.72 and a beta of 0.27. CAMP4 Therapeutics has a 52 week low of $2.86 and a 52 week high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last released its earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.34). The company had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. Analysts anticipate that CAMP4 Therapeutics will post -0.57 earnings per share for the current year.

Insider Activity at CAMP4 Therapeutics

In other CAMP4 Therapeutics news, Director Andrew J. Schwab sold 400,000 shares of CAMP4 Therapeutics stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the transaction, the director directly owned 2,033,270 shares of the company's stock, valued at $8,214,410.80. The trade was a 16.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard A. Young bought 16,378 shares of CAMP4 Therapeutics stock in a transaction dated Monday, August 3rd. The stock was purchased at an average price of $1.65 per share, with a total value of $27,023.70. Following the purchase, the director owned 186,388 shares in the company, valued at approximately $307,540.20. This represents a 9.63% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have purchased 46,031 shares of company stock valued at $99,051 and have sold 593,613 shares valued at $2,504,037. 21.69% of the stock is owned by insiders.

Institutional Investors Weigh In On CAMP4 Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE purchased a new stake in CAMP4 Therapeutics in the 2nd quarter valued at about $78,000. Deutsche Bank AG purchased a new stake in shares of CAMP4 Therapeutics during the second quarter valued at approximately $138,000. Bank of New York Mellon Corp bought a new stake in CAMP4 Therapeutics during the second quarter worth $365,000. EcoR1 Capital LLC bought a new stake in CAMP4 Therapeutics during the fourth quarter worth $1,992,000. Finally, SummitTX Capital L.P. purchased a new position in CAMP4 Therapeutics in the first quarter worth $1,497,000.

CAMP4 Therapeutics Company Profile

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing RNA-based medicines for genetic diseases caused by insufficient production of essential proteins. The company's approach is designed to increase expression of a patient's existing genes rather than replace or edit them.

CAMP4 uses its RegRNA platform to identify regulatory elements in messenger RNA and develop RNA activators, including small activating RNAs, that may stimulate production of targeted proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.